Novel HPTLC Technique for Accurate Measurement of Sitagliptin and Simvastatin in Combined Tablet Formulation-Reference-Cited by-同舟云学术

Novel HPTLC Technique for Accurate Measurement of Sitagliptin and Simvastatin in Combined Tablet Formulation

Published:2025-03-31 Issue:1 Volume:18 Page:665-669
ISSN:2456-2610
Container-title:Biomedical and Pharmacology Journal
language:en
Short-container-title:Biomed. Pharmacol. J.

Author:

Atmakuri Lakshmana Rao¹^ORCID,Thayi Prasanthi¹^ORCID,Potluri Haritha²^ORCID,Alluri Ramesh³^ORCID,Mamidi Satya Venkata Sakuntala⁴,Ghanta Vijaya Kumar⁵^ORCID

Affiliation:

1. 1Department of Pharmaceutical Analysis, V. V. Institute of Pharmaceutical Sciences, Gudlavalleru, Andhra Pradesh, India.

2. 2Department of Chemistry, Seshadri Rao Gudlavalleru Engineering College, Gudlavalleru, Andhra Pradesh, India.

3. 3Department of Pharmacology, Vishnu Institute of Pharmaceutical Education & Research, Narsapur, Telangana, India.

4. 4Department of Pharmacy, Government Polytechnic for Women, Kakinada, Andhra Pradesh, India.

5. 5Department of Pharmacy Practice, KVSR Siddhartha College of Pharmaceutical Sciences, Vijayawada, Andhra Pradesh, India.

Abstract

This method offers a fast, specific and reliable way to measure both Sitagliptin and Simvastatin in a single tablet dosage form. It utilizes a plate with a pre-applied silica gel coating & a unique mobile phase composition for separation. Chloroform, methanol, toluene, and glacial acetic acid were combined in the ratio of 3:4:2:1 (v/v/v/v) and utilized as mobile phase. Exposure is achieved at 210 nm. This technique is linear between 62.5-700 nano gram per spot for Sitagliptin Phosphate & 25-300 nano gram per spot for Simvastatin. The LOD & the LOQ were established to be 10 nano gram per spot & 30 nano gram per spot; 8 nano gram per spot & 25 nano gram per spot respectively. Validation following ICH guidelines confirmed parameters to be within the limits. The method can detect & quantify Sitagliptin & Simvastatin within defined ranges. This approach has the potential for detection with confidence.

Publisher

Oriental Scientific Publishing Company

Reference17 articles.

1. 1. Gallwitz B. Sitagliptin: Profile of a novel DPP-4 inhibitor for the treatment of type 2 diabetes. Drugs Today (Barc), 2007; 43(1): 13-25.

2. 2. Deshmukh VS, Motghare VM, Padwa SL, Jaykare S, Patil J, Pise H. Newer drugs in the management of diabetes mellitus. International Journal of Basic & Clinical Pharmacology, 2013; 2(1): 4-11.

3. 3. Pedersen TR, Tobert JA. Simvastatin: A review. Expert Opinion on Pharmacotherapy, 2004; 5(12): 2583-2596.

4. 4. Ramkumar S, Ajay R, Sudhakshini R. Statin therapy: Review of safety & potential side effects. Acta Cardiologica Sinica, 2016; 32(6): 631-639.

5. 5. Sai Sruthi A, Sai Datri A, Lakshmana Rao A. Development & validation of Sitagliptin & Simvastatin tablets by using RP-HPLC method. International Journal of Applied Pharmaceutical Sciences, 2017; 4(1): 36-43.